Poor Oral Health More Likely for Children With Heart Conditions
THURSDAY, Feb. 10, 2022 (HealthDay News) — Children with heart conditions are more likely to have poor oral health and teeth in fair or poor condition than those without heart conditions, according to research published in the Feb. 11 issue of the U…
Learn MoreClinical Decision Support May Cut Cardiovascular Disease Risk
THURSDAY, Feb. 10, 2022 (HealthDay News) — Use of clinical decision support systems (CDSSs) is associated with improvements in reversible risk for cardiovascular disease (CVD) among patients with the highest levels of baseline risk, according to a st…
Learn MoreCemiplimab Prolongs Survival in Recurrent Cervical Cancer
THURSDAY, Feb. 10, 2022 (HealthDay News) — For patients with recurrent cervical cancer after first-line platinum-containing chemotherapy, survival is significantly longer with cemiplimab than with single-agent chemotherapy, according to a study published in the Feb. 10 issue of the New England Journal of Medicine.
Krishnansu S. Tewari, M.D., from the University of California in Irvine, and colleagues enrolled patients with recurrent cervical cancer who had disease progression after first-line platinum-containing chemotherapy, regardless of their programmed cell death ligand 1 (PD-L1) status. A total of 608 women were randomly assigned to receive either cemiplimab or the investigator’s choice of single-agent chemotherapy (304 in each group).
The researchers found that median overall survival was longer in the cemiplimab group than the chemotherapy group in the overall trial population (12.0 versus 8.5 months; hazard ratio for death, 0.69). In both histologic subgroups (squamous cell carcinoma and adenocarcinoma), the overall survival benefit was consistent. In the overall population, progression-free survival was also longer in the cemiplimab versus chemotherapy group (hazard ratio for disease progression or death, 0.75), and significantly more patients had an objective response (16.4 versus 6.3 percent). An objective response occurred in 18 and 11 percent of cemiplimab-treated patients with PD-L1 expression ≥1 percent and
“The overall survival benefit with cemiplimab was consistent in clinically relevant subgroups, including patients with adenocarcinoma or adenosquamous carcinoma and patients with previous bevacizumab exposure,” the authors write.
The study was funded by Regeneron and Sanofi, the manufacturers of cemiplimab.
Abstract/Full Text (subscription or payment may be required)
Learn MoreCDC Issues Proposed Changes to Opioid Painkiller Guidelines
THURSDAY, Feb. 10, 2022 (HealthDay News) — Proposed changes to voluntary federal guidelines for prescribing opioid painkillers emphasize that doctors should first try other treatments for acute and chronic pain.The nonopioid treatment options suggest…
Learn MoreNew York State Lifts Indoor Mask Mandate
THURSDAY, Feb. 10, 2022 (HealthDay News) — An indoor mask mandate in New York state will end on Thursday, but masks will still be required in schools and for everyone using public transit.For the last two months, customers and workers statewide have …
Learn MoreTest-to-Stay Program Safe for Facilitating In-Person Learning
THURSDAY, Feb. 10, 2022 (HealthDay News) — A statewide test-to-stay (TTS) program involving daily rapid antigen testing is safe and can maximize in-person learning during the pandemic, according to a study published online Feb. 8 in Pediatrics.Elissa…
Learn MorePersistent Black-White Disparities Seen in Cancer Mortality
THURSDAY, Feb. 10, 2022 (HealthDay News) — The overall Black-White disparities are narrowing in cancer incidence but persist in cancer mortality, according to a report published online Feb. 10 in CA: A Cancer Journal for Clinicians.Angela N. Giaquint…
Learn MoreLink Between Analgesics, Incident Tinnitus Explored in Women
THURSDAY, Feb. 10, 2022 (HealthDay News) — The risk for tinnitus is not increased in association with frequent low-dose aspirin use, but it is increased with moderate-dose aspirin and with frequent nonsteroidal anti-inflammatory drug (NSAID) and acet…
Learn More~30 Percent of Seniors Have Sequelae After Acute SARS-CoV-2
THURSDAY, Feb. 10, 2022 (HealthDay News) — Thirty-two percent of adults aged 65 years and older have one or more persistent or new clinical sequelae after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to…
Learn MoreGDM May Up Risk for Range of Later Cardiovascular Conditions
THURSDAY, Feb. 10, 2022 (HealthDay News) — Gestational diabetes mellitus (GDM) is associated with an increased risk for diverse cardiovascular outcomes later in life, according to a study presented at the annual meeting of the Society for Maternal-Fe…
Learn More